Farxiga (dapagliflozin) Approved for the treatment of Chronic Kidney Disease
The FDA has approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure